Tandutinib (sulfate)

Tandutinib (sulfate)

• CAS Number: 387867-14-3
• UNSPSC Description: Tandutinib (MLN518) sulfate is a potent and selective inhibitor of the FLT3 with an IC50 of 0.22 μM, and also inhibits c-Kit and PDGFR with IC50s of 0.17 μM and 0.20 μM, respectively. Tandutinib sulfate can be used for acute myelogenous leukemia (AML)[1][2]. Tandutinib sulfate has the ability to cross the blood-brain barrier[3].
• Target Antigen: Apoptosis; c-Kit; FLT3; PDGFR
• Type: Reference compound
• Related Pathways: Apoptosis;Protein Tyrosine Kinase/RTK
• Field of Research: Cancer
• Assay Protocol: https://www.medchemexpress.com/tandutinib-sulfate.html
• Smiles: O=C(N1CCN(C2=C(C(C=C3OCCCN4CCCCC4)=NC=N2)C=C3OC)CC1)NC5=CC=C(OC(C)C)C=C5.O=S(O)(O)=O
• Molecular Weight: 660.78
• References & Citations: [1]Kelly LM, et al. CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML). Cancer Cell, 2002, 1(5), 421-432.|[2]Griswold IJ, et al. Effects of MLN518, a dual FLT3 and KIT inhibitor, on normal and malignant hematopoiesis. Blood, 2004, 104(9), 2912-2918.|[3]Yang JJ, et al. P-glycoprotein and breast cancer resistance protein affect disposition of tandutinib, a tyrosine kinase inhibitor. Drug Metab Lett. 2010 Dec;4(4):201-12.
• Shipping Conditions: Room temperature
• Clinical Information: No Development Reported